Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fatty Liver Disease, Nonalcoholic: early-phase trial registry
2 of 3 indexed Fatty Liver Disease, Nonalcoholic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Fatty Liver Disease, Nonalcoholic: 3 US clinical trials tracked, 2 recruiting.
Fatty Liver Disease, Nonalcoholic is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Elif Oral, running 1 of these trials.
Enrollment posture brief
Registry condition fatty-liver-disease-nonalcoholic
OPEN 2 | RECR 67% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Fatty Liver Disease, Nonalcoholic lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Fatty Liver Disease, Nonalcoholic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Fatty Liver Disease, Nonalcoholic is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Digoxin In NASH (CODIN)
Yale University
NCT06588699
Thermoacoustic Method for Estimating Liver Fat Fraction
Endra Lifesciences
NCT07321925
Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
Elif Oral
NCT00596934
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Fatty Liver Disease, Nonalcoholic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Fatty Liver Disease, Nonalcoholic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Fatty Liver Disease, Nonalcoholic page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Fatty Liver Disease, Nonalcoholic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Elif Oral sponsors the most Fatty Liver Disease, Nonalcoholic trials on record, review their full trial history before evaluating a specific study. See Elif Oral's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fatty Liver Disease, Nonalcoholic condition card totals 3 registered trials; most-linked intervention metreleptin; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.